Key Takeaways
- • Bill Ackman, a billionaire activist investor with an estimated net worth of $8 billion (as of April 2026), has authorized an experimental mitochondrial transplant procedure for his 26-year-old daughter Lucy, who lost her sight and other motor and language functions following a cerebral hemorrhage in February 2026.
- • The FDA granted expanded access approval in May 2026 under "compassionate use" provisions, permitting the first-ever direct mitochondrial transplant into human eye tissue—a procedure that extracts mitochondria from the patient's leg muscles and injects them into the optic nerve to attempt vision recovery.
- • This marks the first direct ocular application of mitochondrial transplantation technology in humans, despite prior cases of mitochondria being transplanted between other body tissues; the experimental approach addresses the absence of standard treatment options for Lucy's condition.
- • The medical intervention was developed through consultation between Ackman, Mount Sinai Hospital medical staff, and researchers; the procedure represents a departure from conventional treatment protocols in favor of an unproven regenerative approach.
Summary
Bill Ackman, the prominent activist investor and founder of Pershing Square, has approved an experimental mitochondrial transplant procedure for his daughter Lucy following her sudden cerebral hemorrhage in February 2026 at her Brooklyn home. According to reporting from the Washington Post, Lucy experienced loss of vision, motor function, and language skills as a result of the hemorrhagic event and has been undergoing treatment at Mount Sinai Hospital in New York.
Rather than pursue standard treatment protocols, Ackman and his medical team elected to attempt an innovative regenerative therapy involving mitochondrial transplantation. The procedure extracts mitochondria—cellular organelles responsible for energy production—from Lucy's leg muscles and injects them directly into her eyes to attempt repair of the damaged optic nerve. This represents the first documented application of direct mitochondrial transplantation into human ocular tissue, though mitochondrial transfers between other body regions have been performed previously.
The FDA granted approval for the treatment under expanded access provisions in May 2026, commonly referred to as "compassionate use" or "sympathetic use" authorization. This regulatory pathway permits administration of unapproved medical procedures to individual patients with serious conditions who lack alternative treatment options. The decision to pursue experimental therapy reflects the severity of Lucy's condition and the absence of established clinical alternatives to restore her vision and neurological function.
The case underscores both the personal dimensions of medical decision-making for high-net-worth individuals and the evolving regulatory framework permitting access to investigational treatments under humanitarian circumstances. Ackman's involvement may also increase visibility for mitochondrial research and regenerative medicine applications within investor and medical communities.
Rather than pursue standard treatment protocols, Ackman and his medical team elected to attempt an innovative regenerative therapy involving mitochondrial transplantation. The procedure extracts mitochondria—cellular organelles responsible for energy production—from Lucy's leg muscles and injects them directly into her eyes to attempt repair of the damaged optic nerve. This represents the first documented application of direct mitochondrial transplantation into human ocular tissue, though mitochondrial transfers between other body regions have been performed previously.
The FDA granted approval for the treatment under expanded access provisions in May 2026, commonly referred to as "compassionate use" or "sympathetic use" authorization. This regulatory pathway permits administration of unapproved medical procedures to individual patients with serious conditions who lack alternative treatment options. The decision to pursue experimental therapy reflects the severity of Lucy's condition and the absence of established clinical alternatives to restore her vision and neurological function.
The case underscores both the personal dimensions of medical decision-making for high-net-worth individuals and the evolving regulatory framework permitting access to investigational treatments under humanitarian circumstances. Ackman's involvement may also increase visibility for mitochondrial research and regenerative medicine applications within investor and medical communities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.